Switzerland-headquartered iOnctura today announced the appointments of Elizabeth Holt as chief business officer (CBO) and Dr Mark Velleca as chairman of the board of directors.
iOnctura is a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, which was established in 2017 as a spin-out from Germany’s Merck KGaA (MRK: DE). At that time, iOnctura acquired two assets from the healthcare R&D portfolio of Merck and three assets developed by CRT, the commercial arm of Cancer Research UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze